Informed Consent
Item
understand and voluntarily sign an informed consent form.
boolean
C0021430 (UMLS CUI [1])
Age
Item
age ≥ 18 years at time of signing the informed consent form.
boolean
C0001779 (UMLS CUI [1])
Protocol Compliance
Item
able to adhere to the study visit schedule and other protocol requirements
boolean
C0525058 (UMLS CUI [1])
Multiple Myeloma | Thalidomide Discontinued | Dexamethasone High dose Discontinued
Item
participants with multiple myeloma and were enrolled in either thal-mm-003, cc-5013-mm-009, or cc-5013-mm-010 and discontinued study therapy with thalidomide and high-dose dexamethasone or high-dose dexamethasone alone due to:
boolean
C0026764 (UMLS CUI [1])
C0039736 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0011777 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C1444662 (UMLS CUI [3,3])
Dexamethasone High dose Due to Disease Progression | Toxicity | CTCAE Grades
Item
documented disease progression or inability to tolerate the lowest dosing regimen allowed on previous protocol without a grade 3 or 4 toxicity.
boolean
C0011777 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0242656 (UMLS CUI [1,4])
C0600688 (UMLS CUI [2])
C1516728 (UMLS CUI [3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status score 0,1,2
boolean
C1520224 (UMLS CUI [1])
Toxic effect | CTCAE Grades | Thalidomide Related Toxic effect | Dexamethasone Related Toxic effect | Patient Recovered
Item
recovery from thalidomide or dexamethasone-related toxicity to ≤ grade 2 (nci ctc)
boolean
C0600688 (UMLS CUI [1])
C1516728 (UMLS CUI [2])
C0039736 (UMLS CUI [3,1])
C0439849 (UMLS CUI [3,2])
C0600688 (UMLS CUI [3,3])
C0011777 (UMLS CUI [4,1])
C0439849 (UMLS CUI [4,2])
C0600688 (UMLS CUI [4,3])
C0030705 (UMLS CUI [5,1])
C0521108 (UMLS CUI [5,2])
Childbearing Potential Contraceptive methods
Item
females of child-bearing potential (fcbp) must agree to using two methods of contraception
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Allergic Reaction Thalidomide | Hypersensitivity Thalidomide | CTCAE Grades | Exanthema | Peeling of skin
Item
prior development of a ≥ grade 2 allergic reaction/hypersensitivity or prior development of a grade ≥ 3 rash or desquamation while taking thalidomide national cancer institute common toxicity criteria (nci ctc)
boolean
C1527304 (UMLS CUI [1,1])
C0039736 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0039736 (UMLS CUI [2,2])
C1516728 (UMLS CUI [3])
C0015230 (UMLS CUI [4])
C0237849 (UMLS CUI [5])
Therapeutic procedure Against Multiple Myeloma | Investigational Therapy Against Multiple Myeloma | Therapies, Investigational
Item
use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment
boolean
C0087111 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
C0949266 (UMLS CUI [2,1])
C0521124 (UMLS CUI [2,2])
C0026764 (UMLS CUI [2,3])
C0949266 (UMLS CUI [3])
Medical condition Preventing Informed Consent | LABORATORY ABNORMALITIES Preventing Informed Consent | Mental disorder Preventing Informed Consent | Medical condition Resulting in Risk Toxic effect | LABORATORY ABNORMALITIES Resulting in Risk Toxic effect | Mental disorder Resulting in Risk Toxic effect | Study Subject Participation Status
Item
any serious medical condition, laboratory abnormality, or psychiatric illness that will prevent the participant from signing the informed consent form or that will place the participant at an unacceptable risk for toxicity if he/she participates in the study.
boolean
C3843040 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C1853129 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C0004936 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C0021430 (UMLS CUI [3,3])
C3843040 (UMLS CUI [4,1])
C0332294 (UMLS CUI [4,2])
C0035647 (UMLS CUI [4,3])
C0600688 (UMLS CUI [4,4])
C1853129 (UMLS CUI [5,1])
C0332294 (UMLS CUI [5,2])
C0035647 (UMLS CUI [5,3])
C0600688 (UMLS CUI [5,4])
C0004936 (UMLS CUI [6,1])
C0332294 (UMLS CUI [6,2])
C0035647 (UMLS CUI [6,3])
C0600688 (UMLS CUI [6,4])
C2348568 (UMLS CUI [7])
Pregnancy | Breast Feeding
Item
pregnant or lactating females.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
CC 5013 | Malignant Neoplasms | Multiple Myeloma | Basal cell carcinoma | Squamous cell carcinoma of skin | Carcinoma in situ of uterine cervix | Breast Carcinoma In situ
Item
prior therapy with cc-5013; prior history of malignancies, other than multiple myeloma (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast), unless subject has been free of disease for ≥ 5 years
boolean
C1134588 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
C0026764 (UMLS CUI [3])
C0007117 (UMLS CUI [4])
C0553723 (UMLS CUI [5])
C0851140 (UMLS CUI [6])
C0678222 (UMLS CUI [7,1])
C0444498 (UMLS CUI [7,2])
Elapsed Time Since Investigational New Drug Dose Last
Item
more than 4 months has elapsed since the last dose of study drug was administered on study tal mm-003, cc-5013-mm-009, cc-5013-mm-010
boolean
C2826303 (UMLS CUI [1,1])
C1711239 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,4])
C1517741 (UMLS CUI [1,5])
Absolute neutrophil count
Item
absolute neutrophil count (anc) <1,000cells/mm^3 (1.0 x 10^9/l)
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement | Nucleated cells Bone marrow | Plasma Cells
Item
platelet count <75,000/mm^3 (30 x 10^9/l) for those with <50% if the bone marrow nucleated cells re plasma cells; platelet count <30,000/mm^3 (30 x 10^9/l) for those with <50% if the bone marrow nucleated cells re plasma cells
boolean
C0032181 (UMLS CUI [1])
C2738468 (UMLS CUI [2])
C0032112 (UMLS CUI [3])
Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
serum creatinine >2.5mg/dl; serum sgot/ast or sgpt/alt x upper limits of normal (uln)
boolean
C0201976 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
Serum total bilirubin measurement
Item
serum total bilirubin >2.0mg/d/l
boolean
C1278039 (UMLS CUI [1])